ArticleReviews in cardiovascular medicine2025
The Monocyte-to-Lymphocyte Ratio Exhibits A Superior Prognostic Value in Patients with Newly Diagnosed Acute Coronary Syndrome.
Article in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic inflammation critically influences atherosclerotic progression and plaque destabilization. This investigation assessed and compared six lymphocyte-derived inflammatory indices (neutrophil-to-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), systemic immune-inflammation response index (SIIRI)) for predicting major adverse cardiovascular events (MACEs) in treatment-naïve acute coronary syndrome (ACS) patients undergoing coronary angiography. Methods: This study enrolled 1120 patients with newly diagnosed ACS, in which the occurrence of MACEs was monitored. The predictive capacities of the included lymphocyte-derived inflammatory indices were evaluated through receiver operator characteristic (ROC) curve analysis with optimal cutoffs, supplemented by Cox proportional hazards modeling. Results: A total of 265 MACEs (23.66%) were recorded during the 64.20 ± 23.05-month follow-up. Multivariate Cox analyses identified an elevated MLR (hazard ratio (HR) = 2.880, 95% confidence interval (CI) 1.280-6.470; Conclusions: MLR outperformed conventional parameters and five novel lymphocyte-based inflammatory indices in predicting MACEs in ACS patients; thus, the MLR can be established as a robust predictive biomarker. The clinical utility of the MLR extends to risk stratification across key patient subgroups, suggesting potential integration into routine cardiovascular risk assessment protocols.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.